{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:40:33Z","timestamp":1787596833970,"version":"build-2736575974"},"reference-count":48,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.2967\/jnumed.122.264773","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T21:15:22Z","timestamp":1666905322000},"page":"12-19","source":"Crossref","is-referenced-by-count":13,"title":["Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders"],"prefix":"10.2967","volume":"64","author":[{"given":"John P.","family":"Seibyl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2023031310502083000_64.1.12.1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12362"},{"key":"2023031310502083000_64.1.12.2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.038"},{"key":"2023031310502083000_64.1.12.4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-190426","article-title":"Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders","volume":"70","author":"El-Hayek","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"2023031310502083000_64.1.12.5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40120-022-00335-x","article-title":"The humanistic and economic burden of Alzheimer\u2019s disease","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther."},{"key":"2023031310502083000_64.1.12.6","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.37765\/ajmc.2020.88482","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am J Manag Care."},{"key":"2023031310502083000_64.1.12.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"2023031310502083000_64.1.12.8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"key":"2023031310502083000_64.1.12.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2023031310502083000_64.1.12.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"2023031310502083000_64.1.12.11","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3233\/JPD-179001","article-title":"Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff","volume":"7","author":"Braak","year":"2017","journal-title":"J Parkinsons Dis."},{"key":"2023031310502083000_64.1.12.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1299-6"},{"key":"2023031310502083000_64.1.12.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-4008-5"},{"key":"2023031310502083000_64.1.12.14","first-page":"11","article-title":"Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796","volume":"37","author":"Seibyl","year":"1996","journal-title":"J Nucl Med."},{"key":"2023031310502083000_64.1.12.15","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00807-6"},{"key":"2023031310502083000_64.1.12.16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","article-title":"Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort","volume":"74","author":"Jennings","year":"2017","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/mds.28139","article-title":"Clinical and imaging progression in the PARS cohort: long-term follow-up","volume":"35","author":"Siderowf","year":"2020","journal-title":"Mov Disord."},{"key":"2023031310502083000_64.1.12.18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI): establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"2023031310502083000_64.1.12.19","doi-asserted-by":"publisher","DOI":"10.1097\/wad.0000000000000144"},{"key":"2023031310502083000_64.1.12.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"2023031310502083000_64.1.12.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2023031310502083000_64.1.12.22","doi-asserted-by":"crossref","first-page":"12746","DOI":"10.1039\/D0SC02159H","article-title":"Identification of a nanomolar affinity alpha-synuclein fibril imaging probe by ultra-high throughput in silico screening","volume":"11","author":"Ferrie","year":"2020","journal-title":"Chem Sci."},{"key":"2023031310502083000_64.1.12.23","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1177\/0271678X211031035","article-title":"Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans","volume":"41","author":"Baker","year":"2021","journal-title":"J Cereb Blood Flow Metab."},{"key":"2023031310502083000_64.1.12.24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600146"},{"key":"2023031310502083000_64.1.12.25","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","article-title":"Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy","volume":"48","author":"Song","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310502083000_64.1.12.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148981"},{"key":"2023031310502083000_64.1.12.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.01.057"},{"key":"2023031310502083000_64.1.12.28","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1177\/0271678X211018904","article-title":"Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET","volume":"41","author":"Song","year":"2021","journal-title":"J Cereb Blood Flow Metab."},{"key":"2023031310502083000_64.1.12.29","unstructured":"Messerschmidt K Barthel H Brendel M . 18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. April 14, 2022 [Epub ahead of print]."},{"key":"2023031310502083000_64.1.12.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.228346"},{"key":"2023031310502083000_64.1.12.31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","article-title":"Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach","volume":"13","author":"Royse","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"2023031310502083000_64.1.12.32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","article-title":"Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants","volume":"7","author":"Harkins","year":"2015","journal-title":"Alzheimers Res Ther."},{"key":"2023031310502083000_64.1.12.34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000424"},{"key":"2023031310502083000_64.1.12.35","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20112"},{"key":"2023031310502083000_64.1.12.36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301695"},{"key":"2023031310502083000_64.1.12.37","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27361"},{"key":"2023031310502083000_64.1.12.38","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2023031310502083000_64.1.12.39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","article-title":"Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease","volume":"79","author":"Leuzy","year":"2022","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263918"},{"key":"2023031310502083000_64.1.12.42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab431"},{"key":"2023031310502083000_64.1.12.43","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/mds.29148","article-title":"Longitudinal positron emission tomography imaging of presynaptic terminals in early Parkinson\u2019s disease","volume":"37","author":"Delva","year":"2022","journal-title":"Mov Disord."},{"key":"2023031310502083000_64.1.12.44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JCP.0b013e31802e0017","article-title":"Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study","volume":"27","author":"Shang","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"2023031310502083000_64.1.12.45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"key":"2023031310502083000_64.1.12.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2005.06.003"},{"key":"2023031310502083000_64.1.12.47","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.16017"},{"key":"2023031310502083000_64.1.12.48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JPD-191648","article-title":"The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson\u2019s disease","volume":"9","author":"Stephenson","year":"2019","journal-title":"J Parkinsons Dis."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T17:54:25Z","timestamp":1678730065000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2967\/jnumed.122.264773"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264773","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}